{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:26:29Z","timestamp":1793975189731,"version":"4.8.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jvacx.2024.100510","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T12:37:24Z","timestamp":1717677444000},"page":"100510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Why did I participate in an HIV vaccine study? Experiences of participation in the first phase II HIV vaccine trial in Mozambique: An ancillary study using a mixed-method approach"],"prefix":"10.1016","volume":"19","author":[{"given":"Igor P.","family":"Ubisse Capitine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro Marcela","family":"Manhi\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Tembe J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia M.","family":"Ramgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9rgio","family":"Chicumbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Kroidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"De Schacht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvacx.2024.100510_b0005","unstructured":"MISAU, M.r.d.S.d., I.N.d.E.s. INE, and I. Internacional, Inqu\u00e9rito de Indicadores de Imuniza\u00e7\u00e3o, Mal\u00e1ria e HIV\/SIDA em Mo\u00e7ambique (IMASIDA) 2015 - Relat\u00f3rio Final. 2018: Maputo, Mo\u00e7ambique. Rockville, Maryland, EUA: INS, INE e ICF International."},{"issue":"7760","key":"10.1016\/j.jvacx.2024.100510_b0010","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41586-019-1200-9","article-title":"Mapping HIV prevalence in sub-Saharan Africa between 2000 and 2017","volume":"570","author":"Dwyer-Lindgren","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jvacx.2024.100510_b0015","unstructured":"(MISAU), M.d.S., Direc\u00e7\u00e3o Nacional de sa\u00fade P\u00fablica, and Programa Nacional de Controlo das ITS-HIV\/SIDA, Avalia\u00e7\u00e3o do Plano de Acelera\u00e7\u00e3o da Resposta ao HIV e SIDA em Mo\u00e7ambique, 2013 \u2013 2017: Relat\u00f3rio Final. 2020."},{"key":"10.1016\/j.jvacx.2024.100510_b0020","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS), UNAIDS Data 2021. 2021: Geneva, Switzerland."},{"key":"10.1016\/j.jvacx.2024.100510_b0025","unstructured":"Roser, M. and H. Ritchie. \u201cHIV \/ AIDS\u201d. 2019 [cited 2020 15\/05]; Available from: https:\/\/ourworldindata.org\/hiv-aids."},{"key":"10.1016\/j.jvacx.2024.100510_b0030","unstructured":"(MISAU), M.d.S., Direc\u00e7\u00e3o Nacional de Sa\u00fade P\u00fablica, and P.N.d.C.d.I.-. HIV\/SIDA, Plano Estrat\u00e9gico de Ac\u00e7\u00e3o para a Preven\u00e7\u00e3o e Controlo das Infec\u00e7\u00f5es de Transmiss\u00e3o Sexual 2018-2021. 2018."},{"key":"10.1016\/j.jvacx.2024.100510_b0035","unstructured":"Rep\u00fablica de Mo\u00e7ambique: Conselho Nacional de Combate ao HIV\/SIDA, Plano Estrat\u00e9gio Nacional de Resposta ao HIV e SIDA 2015-2019. 2015."},{"issue":"2","key":"10.1016\/j.jvacx.2024.100510_b0040","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/aid.2017.0121","article-title":"Intradermal HIV-1 DNA immunization using needle-free zetajet injection followed by hiv-modified vaccinia virus ankara vaccination is safe and immunogenic in mozambican young adults: A phase I randomized controlled trial","volume":"34","author":"Viegas","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.jvacx.2024.100510_b0045","unstructured":"Instituto Nacional de sa\u00fade (INS). Centros e Unidades Sat\u00e9lites do Instituto Nacional de Sa\u00fade. 2020 [cited 2020 05\/08\/2020]; Available from: https:\/\/www.ins.gov.mz\/centros-e-unidades-satelites."},{"key":"10.1016\/j.jvacx.2024.100510_b0050","unstructured":"HIV Vaccine Trials Network (HVTN). HVTN STUDIES: Ongoing Protocols. 2020 [cited 2020 05\/08]; Available from: https:\/\/www.hvtn.org\/content\/dam\/hvtn\/Science\/studies\/HVTN_Ongoing_Trials_12.20.19.pdf."},{"issue":"Suppl 3","key":"10.1016\/j.jvacx.2024.100510_b0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2019-EDC.23","article-title":"Oc 8491 prepvacc: A phase III, mams adaptive prophylactic Hiv vaccine trial with a second randomisation to compare F\/Taf with Tdf\/Ftc Prep","volume":"4","author":"Joseph","year":"2019","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.jvacx.2024.100510_b0060","unstructured":"World Health Organization (WHO), Creating national and regional frameworks to support HIV Vaccine development in developing countries: Report from a WHO-UNAIDS consultation Lausane, Switzerland, 2-3 September 2004. 2004, World Health Organization: Geneva."},{"issue":"44","key":"10.1016\/j.jvacx.2024.100510_b0065","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1016\/j.vaccine.2011.07.108","article-title":"Conceptual framework for behavioral and social science in HIV vaccine clinical research","volume":"29","author":"Lau","year":"2011","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"10.1016\/j.jvacx.2024.100510_b0070","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1097\/QAI.0b013e31829a3a4d","article-title":"Preparing for the unexpected: the pivotal role of social and behavioral sciences in trials of biomedical HIV prevention interventions","volume":"63","author":"Koblin","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"10.1016\/j.jvacx.2024.100510_b0075","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1007\/s10461-018-2358-0","article-title":"How Biomedical HIV Prevention Trials Incorporate Behavioral and Social Sciences Research: A Typology of Approaches","volume":"23","author":"Corneli","year":"2019","journal-title":"AIDS Behav"},{"key":"10.1016\/j.jvacx.2024.100510_b0080","unstructured":"Stephen B. Hulley, S.R.C., Warren S. Browner, Deborah G. Grady, Thomas B. Newman, Designing clinical research. 2024, Philadelphia, PA: Lippincott Williams and Wilkins."},{"issue":"1","key":"10.1016\/j.jvacx.2024.100510_b0085","article-title":"Socio-behavioral challenges to HIV vaccine trials: Literature review","volume":"4","author":"Inungu","year":"2017","journal-title":"Clinical Research in HIV\/ AIDS"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100510_b0090","doi-asserted-by":"crossref","first-page":"22853","DOI":"10.3402\/gha.v7.22853","article-title":"Factors that influence the willingness of young adults in Dar es Salaam, Tanzania, to participate in phase I\/II HIV vaccine trials","volume":"7","author":"Mbunda","year":"2014","journal-title":"Glob Health Action"},{"issue":"44","key":"10.1016\/j.jvacx.2024.100510_b0095","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1016\/j.vaccine.2013.08.080","article-title":"Willingness to participate in HIV vaccine efficacy trials among high risk men and women from fishing communities along Lake Victoria in Uganda","volume":"31","author":"Asiki","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2024.100510_b0100","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/1471-2458-10-292","article-title":"Balancing collective responsibility, individual opportunities and risks: a qualitative study on how police officers reason around volunteering in an HIV vaccine trial in Dar es Salaam","volume":"10","author":"Tarimo","year":"2010","journal-title":"Tanzania BMC Public Health"},{"key":"10.1016\/j.jvacx.2024.100510_b0105","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/1471-2334-11-283","article-title":"A qualitative evaluation of volunteers' experiences in a phase I\/II HIV vaccine trial in Tanzania","volume":"11","author":"Tarimo","year":"2011","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100510_b0110","doi-asserted-by":"crossref","first-page":"e90938","DOI":"10.1371\/journal.pone.0090938","article-title":"Experiences of social harm and changes in sexual practices among volunteers who had completed a phase I\/II HIV vaccine trial employing HIV-1 DNA priming and HIV-1 MVA boosting in Dar es Salaam, Tanzania","volume":"9","author":"Tarimo","year":"2014","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.jvacx.2024.100510_b0115","doi-asserted-by":"crossref","first-page":"e0224831","DOI":"10.1371\/journal.pone.0224831","article-title":"Perception of potential harm and benefits of HIV vaccine trial participation: A qualitative study from urban Tanzania","volume":"14","author":"Tarimo","year":"2019","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.jvacx.2024.100510_b0120","doi-asserted-by":"crossref","first-page":"e101047","DOI":"10.1371\/journal.pone.0101047","article-title":"Will HIV vaccination reshape HIV risk behavior networks? A social network analysis of drug users' anticipated risk compensation","volume":"9","author":"Young","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100510_b0125","doi-asserted-by":"crossref","first-page":"P209","DOI":"10.1186\/1742-4690-6-S3-P209","article-title":"P15\u201308. Did unblinding affect HIV risk behaviour and risk perception in the HVTN503\/Phambili study?","volume":"6","author":"Gray","year":"2009","journal-title":"Retrovirology"},{"issue":"11","key":"10.1016\/j.jvacx.2024.100510_b0130","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1089\/aid.2013.0136","article-title":"Expectation of volunteers towards the vaccine efficacy of the prime-boost HIV vaccine phase III trial during unblinding","volume":"30","author":"Khowsroy","year":"2014","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100510_b0135","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/eahr.500084","article-title":"Unblinding in randomized controlled trials: A research ethics case","volume":"43","author":"Bhatia","year":"2021","journal-title":"Ethics Hum Res"},{"key":"10.1016\/j.jvacx.2024.100510_b0140","unstructured":"Medicine, I.o., Health and Behavior: The Interplay of Biological, Behavioral, and Societal Influences. 2001, Washington, DC: The National Academies Press. 395."},{"issue":"3","key":"10.1016\/j.jvacx.2024.100510_b0145","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/hpm.812","article-title":"Convergence of behaviour change models for AIDS risk reduction in sub-Saharan Africa","volume":"20","author":"Odutolu","year":"2005","journal-title":"Int J Health Plann Manage"},{"key":"10.1016\/j.jvacx.2024.100510_b0150","first-page":"24","article-title":"Predicting health behaviour: Research and practice with social cognition models","author":"Conner","year":"2005","journal-title":"Safety Science - SAF SCI"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100510_b0155","article-title":"The validity of the theory of planned behaviour for understanding people's beliefs and intentions toward reusing medicines","volume":"9","author":"Alhamad","year":"2021","journal-title":"Pharmacy (Basel)"},{"key":"10.1016\/j.jvacx.2024.100510_b0160","series-title":"Designing and conducting mixed methods research","author":"Creswell","year":"2017"},{"issue":"11","key":"10.1016\/j.jvacx.2024.100510_b0165","doi-asserted-by":"crossref","first-page":"e0206838","DOI":"10.1371\/journal.pone.0206838","article-title":"Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140\/GLA vaccines in a phase II randomized factorial trial design","volume":"13","author":"Viegas","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100510_b0170","doi-asserted-by":"crossref","DOI":"10.1177\/1609406917733847","article-title":"Thematic analysis","volume":"16","author":"Nowell","year":"2017","journal-title":"Int J Qual Methods"},{"key":"10.1016\/j.jvacx.2024.100510_b0175","author":"Johnny","year":"2016","journal-title":"The Coding Manual for Qualitative Researchers"},{"issue":"6 Pt 2","key":"10.1016\/j.jvacx.2024.100510_b0180","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1111\/1475-6773.12117","article-title":"Achieving integration in mixed methods designs-principles and practices","volume":"48","author":"Fetters","year":"2013","journal-title":"Health Serv Res"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100510_b0185","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/tct.13145","article-title":"How to do mixed-methods research","volume":"17","author":"Kajamaa","year":"2020","journal-title":"Clin Teach"},{"issue":"6","key":"10.1016\/j.jvacx.2024.100510_b0190","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups","volume":"19","author":"Tong","year":"2007","journal-title":"Int J Qual Health Care"},{"key":"10.1016\/j.jvacx.2024.100510_b0195","unstructured":"Focus Economics. Mozambique - Exchange Rate. 2015-2019 Janury 15, 2020]; Economic Forecasts from the World's Leading Economists]. Available from: https:\/\/www.focus-economics.com\/country-indicator\/mozambique\/exchange-rate."},{"key":"10.1016\/j.jvacx.2024.100510_b0200","unstructured":"Rep\u00fablica de Mo\u00e7ambique: Minist\u00e9rio da Sa\u00fade (MISAU) and Programa Nacional de Controlo de ITS-HIV\/SIDA (PNC IITS-HIV\/SIDA), Relat\u00f3rio Anual 2019: Relat\u00f3rio Anual das Actividades Relacionadas ao HIV\/SIDA. 2020: Maputo."},{"key":"10.1016\/j.jvacx.2024.100510_b0205","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS), UNAIDS Data 2020. 2020, WHO: Geneva, Switzerland."},{"key":"10.1016\/j.jvacx.2024.100510_b0210","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS), Global HIV Statisctics: Fact Sheet, in WHO. 2020."},{"key":"10.1016\/j.jvacx.2024.100510_b0215","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS), UNAIDS report on the global AIDS epidemic shows that 2020 targets will not be met because of deeply unequal success; COVID-19 risks blowing HIV progress way off course. 2020: Geneva."},{"key":"10.1016\/j.jvacx.2024.100510_b0220","unstructured":"(WHO), W.H.O., Creating national and regional frameworks to support HIV Vaccine development in developing countries: Report from a WHO-UNAIDS consultation Lausane, Switzerland, 2-3 September 2004. 2004, World Health Organization: Geneva."},{"issue":"9","key":"10.1016\/j.jvacx.2024.100510_b0225","doi-asserted-by":"crossref","first-page":"e0183788","DOI":"10.1371\/journal.pone.0183788","article-title":"Volunteer motivators for participating in HIV vaccine clinical trials in Nairobi, Kenya","volume":"12","author":"Nyaoke","year":"2017","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.jvacx.2024.100510_b0230","doi-asserted-by":"crossref","first-page":"e0181702","DOI":"10.1371\/journal.pone.0181702","article-title":"Barriers and facilitators of HIV vaccine and prevention study participation among Young Black MSM and transwomen in New York City","volume":"12","author":"Richardson","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jvacx.2024.100510_b0235","doi-asserted-by":"crossref","unstructured":"Andrasik, M.P., et al., Social Impacts among Participants in HIV Vaccine Trial Network (HVTN) preventive HIV vaccine trials. JAIDS Journal of Acquired Immune Deficiency Syndromes, 2020. Publish Ahead of Print.","DOI":"10.1097\/QAI.0000000000002369"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100510_b0240","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/1740774520948042","article-title":"Behavioral and social science research to support development of educational materials for clinical trials of broadly neutralizing antibodies for HIV treatment and prevention","volume":"18","author":"Valente","year":"2021","journal-title":"Clin Trials"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100510_b0245","doi-asserted-by":"crossref","first-page":"e0231766","DOI":"10.1371\/journal.pone.0231766","article-title":"Sexual behaviour, changes in sexual behaviour and associated factors among women at high risk of HIV participating in feasibility studies for prevention trials in Tanzania","volume":"15","author":"Faini","year":"2020","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100510_b0250","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/QAI.0000000000001143","article-title":"Evaluation of sexual risk behavior among study participants in the TDF2 PrEP study among heterosexual adults in botswana","volume":"73","author":"Gust","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100510_b0255","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.vaccine.2010.10.076","article-title":"\u201cOnce Bitten, Twice Shy\u201d: participant perspectives in the aftermath of an early HIV vaccine trial termination","volume":"29","author":"Newman","year":"2011","journal-title":"Vaccine"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224000834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224000834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T03:43:51Z","timestamp":1723520631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136224000834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":51,"alternative-id":["S2590136224000834"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100510","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Why did I participate in an HIV vaccine study? Experiences of participation in the first phase II HIV vaccine trial in Mozambique: An ancillary study using a mixed-method approach","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100510","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100510"}}